Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of Dabigatran Etexilate (DE) for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Paediatric Patients From Birth to Less Than 2 Years of Age: a Prospective European Non-interventional Cohort Study Based on New Data Collection

Next Previous
Trial Profile

Safety of Dabigatran Etexilate (DE) for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Paediatric Patients From Birth to Less Than 2 Years of Age: a Prospective European Non-interventional Cohort Study Based on New Data Collection

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 09 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms DaPaR
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 26 Jun 2024 Status changed from recruiting to withdrawn prior to enrolment.
  • 05 Dec 2022 Status changed from not yet recruiting to recruiting.
  • 28 Nov 2022 Planned initiation date changed from 15 Nov 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top